Trial
NCT01517776
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Martin-Luther-Universität Halle-Wittenberg
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Gliomas
Intervention
Cilengitide
Why stopped
due to an altered benefit/risk assessment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-07-21